Onconova Therapeutics Company Profile (NASDAQ:ONTX)

Analyst Ratings

Consensus Ratings for Onconova Therapeutics (NASDAQ:ONTX) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $36.73 (920.37% upside)

Analysts' Ratings History for Onconova Therapeutics (NASDAQ:ONTX)
Show:
DateFirmActionRatingPrice TargetActions
3/29/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2015Piper Jaffray Cos.Reiterated RatingOverweight$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2015Janney Montgomery ScottReiterated RatingNeutral -> Fair Value$30.00 -> $15.20View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2015Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Onconova Therapeutics (NASDAQ:ONTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q1($0.19)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/28/2016Q4($0.27)$0.18ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q3($0.32)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.56)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q1($0.63)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015($0.71)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.78)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.89)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.78)($0.87)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Onconova Therapeutics (NASDAQ:ONTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
DateHeadline
07/29/16 08:42 AMOnconova Announces Expiration of Oversubscribed Rights Offering - GlobeNewswire (press release)
07/27/16 08:42 AMOnconova (ONTX), XBiotech (XBIT), Chembio (CEMI) Lead Most Active on Decline
07/27/16 08:38 AMOnconova Announces Expiration of Oversubscribed Rights Offering - [at noodls] - July 27, 2016 NEWTOWN, Pa., July 27, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ('Onconova' or the 'Company'), a Phase 3 clinical-stage biopharmaceutical company focused on discovering ...
07/22/16 05:31 PMOnconova Adjusts Pricing of Rights Offering - GlobeNewswire (press release)
07/22/16 05:31 PMOnconova Therapeutics Incorporated (NASDAQ:ONTX) Sellers ... - Consumer Eagle
07/22/16 05:08 PMOnconova Adjusts Pricing of Rights Offering - [at noodls] - July 22, 2016 NEWTOWN, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ('Onconova' or the 'Company'), a Phase 3 clinical-stage biopharmaceutical company focused on discovering ...
07/20/16 06:26 PMOnconova Announces Enrollment of First Patient in Japan by SymBio - Nasdaq
07/20/16 06:26 PMNew Broker Ratings For Onconova Therapeutics, Inc. (ONTX) - FTSE News
07/19/16 07:01 AMOnconova Announces Enrollment of First Patient in Japan by SymBio - GlobeNewswire (press release)
07/19/16 06:01 AMOnconova Announces Enrollment of First Patient in Japan by SymBio - [GlobeNewswire] - NEWTOWN, Pa., July 19, 2016-- Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the enrollment ...
07/18/16 11:03 AMOnconova Therapeutics Incorporated (NASDAQ:ONTX) Sellers Increased By 163.07% Their Shorts - Consumer Eagle
07/15/16 10:41 AMInstitutional Investor Sentiment About Onconova Therapeutics Inc (NASDAQ:ONTX) Up - Consumer Eagle
07/13/16 05:59 PMIt Seems Onconova Therapeutics Inc Will Go Down. Formed A Few Months Multiple Bottom Pattern - Consumer Eagle
07/13/16 03:53 PMONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and -
07/12/16 05:54 PMOnconova Therapeutics, Inc. (ONTX) Updated Price Targets - FTSE News
07/11/16 05:40 PMToday's Watch List: Onconova Therapeutics, Inc. (NASDAQ:ONTX), PDL BioPharma, Inc. (NASDAQ:PDLI), CompX ... - KC Register
07/08/16 05:42 PMOnconova Therapeutics Incorporated (NASDAQ:ONTX) Sellers Increased By 163.07% Their Shorts - Press Telegraph
07/08/16 05:42 PMIncreased Volatility on Shares of: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Engelwood Daily
07/08/16 05:42 PMOnconova Therapeutics, Inc. (ONTX) Current Analyst Ratings - Fiscal Standard
07/08/16 08:20 AMOnconova Announces Commencement of Subscription Period for Previously Announced Rights Offering - [GlobeNewswire] - NEWTOWN, Pa., July 08, 2016-- Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced today it has ...
07/05/16 05:25 PMTraders Are Bearish Onconova Therapeutics Inc After The Stock Formed Bearish Multiple Bottom Pattern - Press Telegraph
07/05/16 05:25 PMShare Volatility in Focus: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Engelwood Daily
07/03/16 09:52 AMOnconova Therapeutics Incorporated (NASDAQ:ONTX) Shorted Shares Increased By 163.07% - Press Telegraph
07/02/16 08:25 AMRecently Issued Stock Ratings For Onconova Therapeutics, Inc. (ONTX) - Fiscal Standard
07/01/16 06:21 AMOnconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016 - [at noodls] - July 1, 2016 NEWTOWN, Pa., July 01, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ('Onconova' or the 'Company'), a Phase 3 clinical-stage biopharmaceutical company focused on discovering ...
06/30/16 05:54 PMOnconova Therapeutics : Announces Price Range and Change of Key Dates for Rights Offering
06/29/16 05:11 PMOnconova Announces Price Range and Change of Key Dates for Rights Offering - [at noodls] - June 29, 2016 NEWTOWN, Pa., June 29, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ('Onconova' or the 'Company'), a Phase 3 clinical-stage biopharmaceutical company focused on discovering ...
06/28/16 10:30 AMOnconova Therapeutics Incorporated (NASDAQ:ONTX) Shorted Shares Increased 163.07% After Market Selling - Press Telegraph
06/21/16 05:12 PMOnconova Therapeutics : Informs Stockholders of Key Dates Related to Announced Rights Offering
06/20/16 07:45 AMOnconova Informs Stockholders of Key Dates Related to Announced Rights Offering - [GlobeNewswire] - NEWTOWN, Pa., June 20, 2016-- Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided an informational ...
06/15/16 10:13 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) plummeted -11.41%: MTS Systems Corporation (NASDAQ:MTSC ... - KC Register
06/14/16 10:26 AMNetflix (NASDAQ:NFLX) Saws Problems In Numerous Major Asian Markets- Onconova Therapeutics (ONTX ... - Seneca Globe
06/13/16 07:19 AMOnconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting - [at noodls] - June 13, 2016 NEWTOWN, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
06/06/16 04:39 PMETF’s with exposure to Onconova Therapeutics, Inc. : June 6, 2016 -
06/06/16 04:18 PMOnconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting - [at noodls] - June 6, 2016 NEWTOWN, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
06/02/16 08:36 AMOnconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 06:05 PMOnconova Files S-1 Registration Statement for Rights Offering to Shareholders - [at noodls] - June 1, 2016 NEWTOWN, Pa., June 01, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ('Onconova' or the 'Company'), a Phase 3 clinical-stage biopharmaceutical company focused on discovering ...
05/31/16 03:08 PMONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Ar -
05/31/16 08:02 AMOnconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting - [at noodls] - May 31, 2016 NEWTOWN, Pa., May 31, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
05/29/16 06:58 PMPerformance at a Glance on Onconova Therapeutics, Inc. (NASDAQ:ONTX) - HNN - Performance at a Glance on Onconova Therapeutics, Inc. (NASDAQ:ONTX)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Onconova Therapeutics, Inc. (NASDAQ:ONTX)'s stock has performed at various points in its past ...and more »
05/23/16 07:04 PMWill This Move At Onconova Therapeutics Inc. (NASDAQ:ONTX) Benefit Shareholders? - Scibility Media - Scibility MediaWill This Move At Onconova Therapeutics Inc. (NASDAQ:ONTX) Benefit Shareholders?Scibility MediaThe move followed a vote that gave the management the green light to perform a 1-for-10 reverse split of Onconova's shares. Because the reverse split will reduce Onconova Therapeutics Inc. (NASDAQ: ONTX)'s outstanding shares, leaving authorized share ...Onconova Therapeutics (ONTX) Adds New DirectorStreetInsider.comStock Highlights: Starbucks Corporation (NASDAQ:SBUX), ENGlobal Corp. (NASDAQ:ENG), Domino's Pizza, Inc ...Benchmark Monitorall 3 news articles »
05/23/16 03:21 PMONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/23/16 12:22 PMOnconova Therapeutics (ONTX) Adds New Director - StreetInsider.com - Scibility MediaOnconova Therapeutics (ONTX) Adds New DirectorStreetInsider.comOnconova Therapeutics, Inc. (Nasdaq: ONTX) announced that Jack E. Stover has been appointed to its Board of Directors. Currently, Mr. Stover serves as Interim President, CEO and Director of Interpace Diagnostics Group Inc., a company that provides ...Will This Move At Onconova Therapeutics Inc. (NASDAQ:ONTX) Benefit Shareholders?Scibility MediaStock Highlights: Starbucks Corporation (NASDAQ:SBUX), ENGlobal Corp. (NASDAQ:ENG), Domino's Pizza, Inc ...Benchmark Monitorall 3 news articles »
05/22/16 07:07 AM8:07 am Onconova Therapeutics announces 1:10 reverse stock split; will take effect at 5:00 PM ET on May 31 -
05/21/16 06:36 PMRevenue Update on Onconova Therapeutics Inc(NASDAQ:ONTX) - Trade Calls - Revenue Update on Onconova Therapeutics Inc(NASDAQ:ONTX)Trade CallsOnconova Therapeutics Inc(NASDAQ:ONTX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 11, 2016. Company reported revenue of $1.47M. Analysts estimated a revenue of $1.34M. Earnings per ...Onconova Therapeutics Incorporated (NASDAQ:ONTX) Short Interest Increased By 5.59%The Postall 3 news articles »
05/21/16 12:09 AMOnconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split - NEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual ...
05/20/16 07:02 PMWatch List: Asanko Gold (NYSEMKT:AKG), Onconova Therapeutics (NASDAQ:ONTX), Canadian Solar Inc. (NASDAQ ... - KC Register - Watch List: Asanko Gold (NYSEMKT:AKG), Onconova Therapeutics (NASDAQ:ONTX), Canadian Solar Inc. (NASDAQ ...KC RegisterOnconova Therapeutics, Inc. (NASDAQ:ONTX) reported financial results for the first quarter ended March 31, 2016. Total net revenue was $1.5 million for the first quarter of 2016 compared to $0.1 million for the first quarter of 2015. Research and ...and more »
05/20/16 07:02 PMOnconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split - Nasdaq - Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock SplitNasdaqNEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results ...Onconova to reverse split stock 1:10 at the end of the month, post-split trading to commence June 1Seeking Alphaall 2 news articles »
05/20/16 07:13 AMOnconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split - [at noodls] - May 20, 2016 NEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products ...
05/13/16 01:14 AMEarnings Report: Onconova Therapeutics Inc (NASDAQ:ONTX) - News Oracle - News OracleEarnings Report: Onconova Therapeutics Inc (NASDAQ:ONTX)News OracleLast Trade: The Company rose 16.71% and finished at $0.560. The daily volume was measured at 1.44 million shares. The 52-week high of the share price is $4.00 and the 52-week low is $0.32. The company has a market cap of $17.54 million. Its latest ...and more »

Social

About Onconova Therapeutics

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases, cellular metabolism or cell division. The Company's lead product candidate, rigosertib, is being tested as a single agent and in combination with azacitidine, in clinical trials of patients with myelodysplastic syndromes (MDS) and related cancers. The Company is continuing the Phase II portion of a clinical trial of rigosertib oral in combination with azacitidine for patients with MDS and acute myelogenous leukemia (AML).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONTX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.60
  • 50 Day Moving Average: $5.24
  • 200 Day Moving Average: $5.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $9.86M
  • Beta: 0.04
  • Current Year EPS Consensus Estimate: $-7.40 EPS
  • Next Year EPS Consensus Estimate: $-6.90 EPS
Additional Links:
Onconova Therapeutics (NASDAQ:ONTX) Chart for Saturday, July, 30, 2016